Physician profile
Mark Foster
NPI 1245294040
$2,945.65
in general payments reported to CMS, 2019-2025
25 companies · $617 in 2025
The $617 reported for 2025 was more than what 77% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $274 · 2020: $190 · 2021: $371 · 2022: $353 · 2023: $724 · 2024: $416 · 2025: $617.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,757.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,757.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $567.33 | 2019-2025 | Shingrix, Trelegy Ellipta, Arexvy |
| Pfizer INC. | $549.22 | 2020-2025 | |
| Novo Nordisk INC | $299.19 | 2019-2025 | Wegovy, Rybelsus, Ozempic |
| Lilly USA, LLC | $250.38 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $225.31 | 2022-2023 | |
| Exact Sciences Corporation | $146.10 | 2023-2025 | Cologuard Collection Kit |
| Merck Sharp & Dohme LLC | $144.33 | 2019-2025 | Gardasil 9, Vaxneuvance, Gardasil |
| Boehringer Ingelheim Pharmaceuticals, INC. | $123.05 | 2019-2024 | Jardiance |
| Astrazeneca Pharmaceuticals Lp | $109.89 | 2019-2025 | Airsupra |
| Sanofi-Aventis U.S. LLC | $86.71 | 2020-2022 | |
| Amgen INC. | $78.65 | 2024-2025 | Repatha, Otezla |
| Teva Pharmaceuticals USA, INC. | $50.24 | 2019-2021 | |
| Idorsia Pharmaceuticals US INC | $47.04 | 2022-2023 | Quviviq |
| Novartis Pharmaceuticals Corporation | $32.54 | 2022 | |
| Insulet Corporation | $32.51 | 2022-2023 | Omnipod |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $29.42 | 2022 | |
| Inspire Medical Systems, INC. | $26.82 | 2025 | Inspire |
| Janssen Pharmaceuticals, INC | $25.36 | 2021 | |
| Antares Pharma, INC. | $22.72 | 2025 | Xyosted |
| Medtronic Vascular, INC. | $18.27 | 2020 | |
| Eisai INC. | $16.76 | 2021 | |
| Abbott Laboratories | $16.55 | 2019 | |
| Allergan, INC. | $15.93 | 2019 | |
| Amarin Pharma, INC. | $15.78 | 2019 | |
| Amneal Pharmaceuticals LLC | $15.55 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Foster listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.